Biosimilars – Market Events And Forecast – Oncology

In 2019, sales of branded monoclonal antibody biologics in oncology exceeded $18 billion across the major markets (United States, EU5, and Japan), and the sales of biosimilars in these regions totaled $770 million. Throughout our 2019-2029 forecast period, increasing numbers of branded biologics are set to lose patent protection, with biosimilars expected to enter the market and eroding both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and region.

Table of contents

  • Biosimilars - Market Events And Forecast - Oncology
    • Market Forecast in the Major Pharmaceutical Markets
      • Major-Market Forecast: Oncology Monoclonal Antibodies
      • Terminology of Oncology Monoclonal Antibodies
        • Terminology of G-CSFs
          • Major-Market Forecast: G-CSFs
      • Overarching Forecast Assumptions
        • Overview of Oncology MAb Brands in the Forecast
          • Biosimilar Entry Assumptions for MAbs in Oncology
        • Overview of Oncology MAb Biosimilars Assumptions
          • Overview of G-CSF Brands in the Forecast
            • Overview of Approved G-CSF Brands
            • Biosimilar Entry Assumptions for G-CSF Brands
          • Overview of Assumptions for Biosimilars of G-CSFs
            • United States
            • Europe
            • Japan
        • Drug-Specific Forecast Assumptions
          • Avastin
            • Outlook for Avastin
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Avastin Sales Forecast in the United States: 2019-2029
            • Avastin Sales Forecast in the EU5: 2019-2029
            • Avastin Sales Forecast in Japan: 2019-2029
          • Cyramza
            • Outlook for Cyramza
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Cyramza Sales Forecast in the United States: 2019-2029
            • Cyramza Sales Forecast in the EU5: 2019-2029
            • Cyramza Sales Forecast in Japan: 2019-2029
          • Erbitux
            • Outlook for Erbitux
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Erbitux Sales Forecast in the United States: 2019-2029
            • Erbitux Sales Forecast in the EU5: 2019-2029
            • Erbitux Sales Forecast in Japan: 2019-2029
          • Herceptin
            • Outlook for Herceptin
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Roche HER2-Franchise Defense Strategies
            • Herceptin Sales Forecast in the United States: 2019-2029
            • Herceptin Sales Forecast in the EU5: 2019-2029
            • Herceptin Sales Forecast in Japan: 2019-2029
          • Kadcyla
            • Outlook for Kadcyla
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Kadcyla Sales Forecast in the United States: 2019-2029
            • Kadcyla Sales Forecast in the EU5: 2019-2029
            • Kadcyla Sales Forecast in Japan: 2019-2029
          • Perjeta
            • Outlook for Perjeta
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Perjeta Sales Forecast in the United States: 2019-2029
            • Perjeta Sales Forecast in the EU5: 2019-2029
            • Perjeta Sales Forecast in Japan: 2019-2029
          • Rituxan / MabThera
            • Outlook for Rituxan / MabThera
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Roche CD20-Franchise Defense Strategies
            • Rituxan Sales Forecast in Oncology for the United States: 2019-2029
            • MabThera Sales Forecast in Oncology for the EU5: 2019-2029
            • Rituxan Sales Forecast in Oncology for Japan: 2019-2029
            • Rituxan Sales Forecast for the United States (Immunology and Oncology): 2019-2029
            • MabThera Sales Forecast for the EU5 (Immunology and Oncology): 2019-2029
          • Vectibix
            • Outlook for Vectibix
            • First Major-Market Biosimilar Entrants
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Vectibix Sales Forecast in the United States: 2019-2029
            • Vectibix Sales Forecast in the EU5: 2019-2029
            • Vectibix Sales Forecast in Japan: 2019-2029
          • Yervoy
            • Outlook for Yervoy
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Ex-Manufacturer Price Assumptions
            • Yervoy Sales Forecast in the United States: 2019-2029
            • Yervoy Sales Forecast in the EU5: 2019-2029
            • Yervoy Sales Forecast in Japan: 2019-2029
          • Neupogen / Gran
            • Outlook for Neupogen / Gran
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Order of Entry in Japan
            • Biosimilars Uptake Assumptions
            • Neupogen Sales Forecast in the United States: 2019-2029
            • Neupogen Sales Forecast in the EU5: 2019-2029
            • Gran Sales Forecast in Japan: 2019-2029
          • Neulasta / G-Lasta
            • Outlook for Neulasta
            • First Major-Market Biosimilar Entrants
            • Order of Entry in the United States
            • Order of Entry in the EU5
            • Biosimilar Uptake Assumptions
            • Biosimilar and Brand Net Cost Assumptions
            • Neulasta Sales Forecast in the United States: 2019-2029
            • Neulasta Sales Forecast in the EU5: 2019-2029
            • G-Lasta Sales Forecast in Japan: 2019-2029

      launch Related Market Assessment Reports